The pharmaceutical giant Eli Lilly announced recently that they would be selling Humalog, their most popular fast-acting insulin, at half price—a reduction that still leaves the drug at $137.35 a vial. This decision comes in the face of intensifying criticism over consistent increases in the drug’s price: according to the Healthcare Cost Institute, the cost…